La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

SAB Biotherapeutics Salute del bilancio

Salute finanziaria criteri di controllo 3/6

SAB Biotherapeutics ha un patrimonio netto totale di $46.1M e un debito totale di $615.8K, che porta il suo rapporto debito/patrimonio netto a 1.3%. Le sue attività totali e le sue passività totali sono rispettivamente $61.9M e $15.8M.

Informazioni chiave

1.3%

Rapporto debito/patrimonio netto

US$615.82k

Debito

Indice di copertura degli interessi	n/a
Contanti	US$37.33m
Patrimonio netto	US$46.12m
Totale passività	US$15.77m
Totale attività	US$61.89m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified

Apr 17

Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week

Jan 20

Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues

Nov 19

Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Nov 18

SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial

Sep 28

What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates

Aug 12

SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03

Aug 10

Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term

Apr 06

SAB Biotherapeutics: Advancing A New Class Of Immunotherapies Leveraging Polyclonal Antibodies

Dec 02

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $39.6M ) di SABS superano le sue passività a breve termine ( $7.6M ).

Passività a lungo termine: Le attività a breve termine di SABS ( $39.6M ) superano le sue passività a lungo termine ( $8.2M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: SABS ha più liquidità del suo debito totale.

Riduzione del debito: Dati insufficienti per determinare se il rapporto debito/patrimonio netto di SABS si sia ridotto negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: SABS ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: SABS ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 41.2 % ogni anno

SAB Biotherapeutics Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

SAB Biotherapeutics, Inc. announced delayed 10-Q filing

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

SAB Biotherapeutics Receives a Written Notification from The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Recent updates

Price target decreased by 35% to US$13.00

Consensus revenue estimates increase by 30%

Sab Bio Announces Founding of Clinical Advisory Board to Guide the Development of Sab-142 for Type 1 Diabetes

SAB Biotherapeutics, Inc. Appoints Lucy to as Chief Financial Officer, Effective August 12, 2024

SAB Biotherapeutics, Inc., Annual General Meeting, Jun 27, 2024

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

SAB Biotherapeutics, Inc. announced delayed 10-Q filing

SAB Biotherapeutics, Inc. Appoints Jay Skyler, Md, to the Board of Directors

SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update

Price target increased by 25% to US$25.00

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

SAB Biotherapeutics, Inc. Announces CEO Changes

SAB Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

SAB Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Shareholder dilution

SAB Biotherapeutics Announces Commencement of the Human Phase 1 Clinical Trial with Sab-142

SAB Biotherapeutics, Inc. Appoints Katie Ellias to the Board of Directors

Consensus revenue estimates increase by 61%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 22% to US$2.50

SAB Biotherapeutics, Inc. Appoints Michael G. King Jr. as Chief Financial Officer

SAB Biotherapeutics Appoints Andrew Moin to Board of Directors

Consensus revenue estimates decrease by 51%, EPS upgraded

Consensus revenue estimates decrease by 81%, EPS upgraded

SAB Biotherapeutics, Inc., Annual General Meeting, Jun 29, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

SAB Biotherapeutics, Inc. Announces First Publication of Promising Nonclinical Data for Sab-183 Against Pneumonic Plague in the Journal Antibodies

SAB Biotherapeutics Announces Progress on U.S. FDA's Phased Review of Company's DiversitAb Platform

SAB Biotherapeutics, Inc. Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference

Consensus revenue estimates decrease by 56%, EPS upgraded

Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified

Full year 2022 earnings released: US$0.43 loss per share (vs US$0.63 loss in FY 2021)

Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week

SAB Biotherapeutics, Inc. Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

SAB Biotherapeutics, Inc. announced that it has received $7.884 million in funding

SAB Biotherapeutics Inc. Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes

Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues

Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference

SAB Biotherapeutics Receives a Written Notification from The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Sab Biotherapeutics Unveils New Data At Isirv Options XI Conference Validating SAB-176 Proof of Concept

SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial

SAB Biotherapeutics to Present New Data At Isirv Options Xi Conference on Sab-176 Phase 2A Influenza Trial and Sab-185’S Effectiveness Against Multiple Covid-19 Variants

Consensus revenue estimates fall by 41%

What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03

SAB Biotherapeutics, Inc. Appoints Rear Admiral Scott Giberson to Board of Directors

SAB Biotherapeutics, Inc. Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical Officer

SAB Biotherapeutics, Inc., Annual General Meeting, Jul 06, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$10.35

High number of new directors

High number of new directors

Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term

SAB Biotherapeutics, Inc. Appoints Mark J. Ratain to Its Board of Scientific Advisors

Consensus revenue estimates fall by 25%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$12.63

SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations

SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19

SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19

High number of new directors

Consensus EPS estimates increase to -US$0.23

SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus